Alpha Tau Medical Statistics
Total Valuation
DRTS has a market cap or net worth of $354.20 million. The enterprise value is $288.25 million.
Important Dates
The next estimated earnings date is Tuesday, November 18, 2025, after market close.
| Earnings Date | Nov 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DRTS has 85.04 million shares outstanding. The number of shares has increased by 4.48% in one year.
| Current Share Class | 85.04M |
| Shares Outstanding | 85.04M |
| Shares Change (YoY) | +4.48% |
| Shares Change (QoQ) | +14.20% |
| Owned by Insiders (%) | 16.16% |
| Owned by Institutions (%) | 1.87% |
| Float | 57.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.97 |
| P/TBV Ratio | 4.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.52, with a Debt / Equity ratio of 0.15.
| Current Ratio | 10.52 |
| Quick Ratio | 9.77 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -121.82 |
Financial Efficiency
Return on equity (ROE) is -43.83% and return on invested capital (ROIC) is -25.15%.
| Return on Equity (ROE) | -43.83% |
| Return on Assets (ROA) | -22.66% |
| Return on Invested Capital (ROIC) | -25.15% |
| Return on Capital Employed (ROCE) | -36.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$281,640 |
| Employee Count | 125 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DRTS has paid $166,000 in taxes.
| Income Tax | 166,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.09% in the last 52 weeks. The beta is 1.07, so DRTS's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +90.09% |
| 50-Day Moving Average | 3.92 |
| 200-Day Moving Average | 3.22 |
| Relative Strength Index (RSI) | 56.19 |
| Average Volume (20 Days) | 63,981 |
Short Selling Information
The latest short interest is 93,955, so 0.11% of the outstanding shares have been sold short.
| Short Interest | 93,955 |
| Short Previous Month | 101,596 |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.16% |
| Short Ratio (days to cover) | 1.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -37.52M |
| Pretax Income | -35.04M |
| Net Income | -35.21M |
| EBITDA | -36.45M |
| EBIT | -37.52M |
| Earnings Per Share (EPS) | -$0.48 |
Full Income Statement Balance Sheet
The company has $79.70 million in cash and $13.31 million in debt, giving a net cash position of $66.39 million or $0.78 per share.
| Cash & Cash Equivalents | 79.70M |
| Total Debt | 13.31M |
| Net Cash | 66.39M |
| Net Cash Per Share | $0.78 |
| Equity (Book Value) | 86.62M |
| Book Value Per Share | 1.02 |
| Working Capital | 77.62M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$21.59 million and capital expenditures -$5.33 million, giving a free cash flow of -$26.92 million.
| Operating Cash Flow | -21.59M |
| Capital Expenditures | -5.33M |
| Free Cash Flow | -26.92M |
| FCF Per Share | -$0.32 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.48% |
| Shareholder Yield | -4.48% |
| Earnings Yield | -9.93% |
| FCF Yield | -7.59% |
Analyst Forecast
The average price target for DRTS is $9.00, which is 116.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 116.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |